The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. Predicted molecular weight: 57 kDa.
Use at an assay dependent dilution.
FunctionThrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner. Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Tissue specificityExpressed predominantly in liver. Also present in plasma.
Involvement in diseaseThrombophilia due to heparin cofactor 2 deficiency
Sequence similaritiesBelongs to the serpin family.
DomainThe N-terminal acidic repeat region mediates, in part, the glycosaminoglycan-accelerated thrombin inhibition.
Post-translational modificationsPhosphorylation sites are present in the extracellular medium.